Welcome to Caedo Oncology
We create improved treatment options for cancer patients through unique immunotherapy opportunities
CO-1 is a novel bifunctional anti-CD47 monoclonal antibody which
efficiently block SIRPα – CD47 interactions and unlike other CD47 monoclonal antibodies, induces direct and fast programmed cell death of cancer cells.
Our team of scientist and advisors come from different scientific backgrounds – such as biology, molecular biology, immunology, and chemistry. In addition, the team also includes people with broad life science business experience.
Meet our team